[Successful treatment with reduced-intensity stem cell transplantation for primary myelofibrosis].
A 60-year-old man was found to have anemia and leukocytosis from a health examination, and diagnosed with primary myelofibrosis (PMF). He was treated with low-dose melphalan but required frequent transfusions of red blood cells, and his splenomegaly enlarged. He received reduced-intensity stem cell transplantation (RIST)from an HLA-identical unrelated donor. The recovery of hematopoiesis was delayed due to the small number of transplanted cells (0.4 x 10(8)/kg). Splenomegaly and myelofibrosis gradually improved, and transfusion was not necessary 6 months later. He died of pneumonia about 1 year after transplantation. However, this case suggests that RIST is an effective treatment for PMF with giant splenomegaly.
Ito
Satomi
S
Dept. of Hematology, Kanagawa Cancer Center, Yokohama City University Graduate School of Medicine.
Hagihara
Maki
M
Motohashi
Kenji
K
Maruta
Atsuo
A
Ishigatsubo
Yoshiaki
Y
Gomi
Seiji
S
Kanamori
Heiwa
H
D017809:Fatal Outcome; D006801:Humans; D008297:Male; D008558:Melphalan / Q000627:therapeutic use; D008875:Middle Aged; D019653:Myeloablative Agonists / Q000627:therapeutic use; D055728:Primary Myelofibrosis / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000601:surgery*; D033581:Stem Cell Transplantation; D014057:Tomography, X-Ray Computed
D019653:Myeloablative Agonists; D008558:Melphalan